<DOC>
	<DOCNO>NCT01722682</DOCNO>
	<brief_summary>The goal study evaluate safety efficacy bone marrow ( BM ) site pancreatic islet transplantationin human . Our hypothesis BM represent well site liver ( currently location choice procedure ) thank potential capacity favor islet engraftment . To address hypothesis propose herein randomize phase II trial compare BM liver sit islet transplantation T1D patient .</brief_summary>
	<brief_title>Bone Marrow v Liver Site Islet Transplantation</brief_title>
	<detailed_description>The study phase II , single center , open label , pilot study . We recruit 12 patient T1D randomly ( 1:1 ) assign receive islet either liver portal venous circulation ( standard procedure ; arm A , n=6 ) directly BM level iliac crest ( arm B , n=6 ) . Patients select eligible islet Tx base local practice guideline .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>diabetic patient eligible pancreatic islet transplantation base local accepted practice guideline . This include least : ) clinical history compatible T1D insulindependence &gt; 5 year ; b ) undetectable stimulate ( arginine MMTT ) Cpeptide level ( &lt; 0.3 ng/mL ) 12 month transplant c ) presence severe hypoglycaemic event presence hematologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes</keyword>
</DOC>